@article{7eabdee6316d4842b71e1da022c273d0,
title = "Evaluation of non-tissue culture-versus tissue culture-treated microplates for oritavancin susceptibility testing",
keywords = "Non-tissue culture treated, Oritavancin, Polysorbate 80, Tissue culture treated, broth microdilution susceptibility testing",
author = "Qun Yan and Karau, {Melissa J.} and Robin Patela",
note = "Funding Information: R.P. reports grants from CD Diagnostics, BioFire, Curetis, Merck, Hutchison Biofilm Medical Solutions, Accelerate Diagnostics, Allergan, and The Medicines Company. R.P. is a consultant to Curetis, Qvella, Specific Technologies, Selux Dx, GenMark Diagnostics, PathoQuest, and Genentech; monies are paid to the Mayo Clinic. In addition, R.P. has been issued a patent on a Bordetella pertussis/B. parapertussis PCR assay, a patent on a device/method for sonication, with royalties paid by Samsung to the Mayo Clinic, and a patent on an antibiofilm substance. R.P. has served on an Actelion data monitoring board. R.P. receives travel reimbursement from ASM and IDSA, an editor{\textquoteright}s stipend from ASM and IDSA, and honoraria from the NBME, Up-to-Date, and the Infectious Diseases Board Review Course.",
year = "2018",
month = apr,
doi = "10.1128/JCM.02001-17",
language = "English (US)",
volume = "56",
journal = "Journal of Clinical Microbiology",
issn = "0095-1137",
publisher = "American Society for Microbiology",
number = "4",
}